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Abstract
Background: Antisense oligonucleotides (AOs) can interfere with exon recognition and intron
removal during pre-mRNA processing, and induce excision of a targeted exon from the mature
gene transcript. AOs have been used in vitro and in vivo to redirect dystrophin pre-mRNA
processing in human and animal cells. Targeted exon skipping of selected exons in the dystrophin
gene transcript can remove nonsense or frame-shifting mutations that would otherwise have lead
to Duchenne Muscular Dystrophy, the most common childhood form of muscle wasting.
Results: Although many dystrophin exons can be excised using a single AO, several exons require
two motifs to be masked for efficient or specific exon skipping. Some AOs were inactive when
applied individually, yet pronounced exon excision was induced in transfected cells when the AOs
were used in select combinations, clearly indicating synergistic rather than cumulative effects on
splicing. The necessity for AO cocktails to induce efficient exon removal was observed with 2
different chemistries, 2'-O-methyl modified bases on a phosphorothioate backbone and
phosphorodiamidate morpholino oligomers. Similarly, other trends in exon skipping, as a
consequence of 2'-O-methyl AO action, such as removal of additional flanking exons or variations
in exon skipping efficiency with overlapping AOs, were also seen when the corresponding
sequences were prepared as phosphorodiamidate morpholino oligomers.
Conclusion: The combination of 2 AOs, directed at appropriate motifs in target exons was found
to induce very efficient targeted exon skipping during processing of the dystrophin pre-mRNA. This
combinatorial effect is clearly synergistic and is not influenced by the chemistry of the AOs used to
induce exon excision. A hierarchy in exon skipping efficiency, observed with overlapping AOs
composed of 2'-O-methyl modified bases, was also observed when these same sequences were
evaluated as phosphorodiamidate morpholino oligomers, indicating design parameters established
with one chemistry may be applied to the other.
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Antisense oligonucleotides (AOs) can be used to modify
gene expression through the induction of a variety of
mechanisms. Oligodeoxyribonucleotides can be used to
target a gene transcript for RNaseH induced degradation,
whereas oligomers composed of modified bases can redi-
rect gene expression through RNA silencing [1], suppress-
ing specific mRNA translation [2-4], enhancing mRNA
stability [5] and redirecting pre-mRNA splicing patterns
[6].
Protein-truncating mutations in the dystrophin gene typi-
cally lead to Duchenne muscular dystrophy (DMD), the
most common severe childhood form of muscle wasting
(review, [7]). Although the size of this gene, with 79 exons
spanning some 2,400 kb, and distribution of expression
have posed major challenges for gene repair or replace-
ment strategies, these features have opened other avenues
for intervention, such as AO induced exon skipping. Tar-
geted removal of selected exons can excise or by-pass pro-
tein-truncating mutations from the dystrophin pre-mRNA
during the splicing process. The application of AOs to
induce targeted exon skipping in the dystrophin gene has
been reported by several groups, examining different ani-
mal models [8-11], regions of the human dystrophin gene
transcript [12-14] and a variety of AO chemistries [12,15-
18]. We have recently reported a comprehensive list of
AOs that can induce skipping of all dystrophin exons,
excluding the first and last exons [19]. Many exons could
be targeted for excision from the mature dystrophin
mRNA with a high level of efficiency and in some cases,
two exons were consistently removed using a single AO,
suggesting tight coordination of recognition of these
exons with intron removal. However, some exons were
found to be extremely difficult to dislodge, despite the
evaluation of many AOs directed to the target exon. These
"recalcitrant" exons could be efficiently excised from the
mature mRNA in response to some select combinations of
apparently ineffective AOs.
AOs composed of 2'-O-methyl modified bases on a phos-
phorothioate backbone (2OMeAO) have been used
extensively to induce targeted exon skipping in the dys-
trophin gene transcript and have some advantages over
the phosphorodiamidate morpholino oligomers (PMO),
including ease and cost of production, and efficient in
vitro delivery when administered as cationic lipoplexes.
However, PMOs appear to be better suited to in vivo appli-
cation, where the increased stability and cellular uptake of
uncomplexed compounds allows for higher levels of sus-
tained dystrophin exon skipping, as well as an excellent
safety profile [20-22]. In this report, we describe optimi-
zation and excision of recalcitrant dystrophin exons from
the mature mRNA using AO cocktails for enhanced effi-
ciency and/or specificity. The use of either 2OMeAOs or
PMOs does not seem to influence exon skipping trends,
indicating optimization of AO design with the 2OMe
chemistry should be directly applicable to PMOs.
Results and discussion
We have designed AOs capable of individually excising 77
of the 79 exons from the dystrophin gene transcript [19],
yet no universal motif has been identified as a reliable tar-
get for the consistent redirection of dystrophin pre-mRNA
splicing. The rationale in our approach to AO design was
to first direct AOs at motifs obviously implicated in exon
processing and recognition, such as the acceptor and
donor splice sites, as well as exonic splicing enhancers as
predicted by ESEfinder [23]. Once some dystrophin exon
skipping was observed in AO-transfected human myo-
genic cells, a series of overlapping AOs were then designed
to target that area, in an attempt to develop more effective
AOs. In many cases, a single AO was eventually developed
that would induce substantial levels of targeted exon skip-
ping, and the study would then move to another dys-
trophin exon. Since this is regarded as a work in progress,
the dystrophin exons were regarded as a reference point
and classified into four types based upon the ease of exci-
sion from the mature mRNA [19]. Type 1 dystrophin
exons are removed most efficiently (greater than 30%
after in vitro transfection at 100 nM), Type 2 are less easily
dislodged, while Type 3 exons are poorly excised. Type 4
dystrophin exons are "special cases", where either a single
AO removed multiple exons, or multiple AOs are required
to excise a single targeted exon.
We observed that approximately two out of three AOs
applied to the dystrophin pre-mRNA were able to induce
some exon skipping, but there was considerable variation
in levels of induced exon removal, relative to the intact
dystrophin transcript. In some cases, the exon excision
only occurred at low levels, or was sporadic. The fre-
quency of these sporadic exon skipping events was greater
than that observed in untreated cells, indicating some
interference with the splicing process. However, the lack
of reproducibility, or any dose-dependant responses indi-
cated further refinement was essential.
Dystrophin exon 20 skipping
Dystrophin exon 19 was one example of a Type 1 exon
that was very easy to dislodge from the mature mRNA,
with every AO directed at acceptor, donor and intra-
exonic splicing enhancers able to induce some dystrophin
exon skipping [24,25]. In contrast, the following exon in
the dystrophin pre-mRNA was one that proved a much
greater challenge. Eighteen AOs were prepared to anneal
to predicted splice motifs across exon 20 (Additional file
1, Fig 1a), and the majority induced either no, or sporadic
exon skipping (data not shown). Several different AO
cocktails were then evaluated and found to induce somePage 2 of 8
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ciency between the different preparations was evident
(Figures 1b–f). One preparation, consisting of equal
amounts of H20A(+44+71) and H20A(+147+168), was
found to be more efficient at exon 20 excision than other
combinations and induced the shortened transcript to lev-
els of 36% when compared to the full length product after
transfection at 25 nM (Figure 1e). Eventually, a single AO,
H20A(+39+69), was developed to induce exon 20 skip-
ping, but this was still not as efficient as the cocktail of
H20A(+44+71) and H20A(+147+168) (Figure 1g). Fur-
ther combinations of AOs were evaluated including AO
H20A(+39+69), the most active when used individually,
and the non-overlapping AO from the most effective AO
cocktail, H20A(+147+168). Unexpectedly, this particular
combination was consistently not as efficient at exon 20
excision and only resulted in 13% of the shortened prod-
uct (Figure 1f), even though there is considerable overlap
between the annealing coordinates of H20A(+44+71) and
H20A(+39+69). These two AOs targeted essentially the
same predicted ESE motifs, with the only differences
being H20A(+44+71) extended only one base into a puta-
tive SC35 motif, and H20A(+39+69) overlapped one base
of a predicted SRp40 motif. Although it seems unlikely
that these subtle annealing differences would contribute
to the variation in exon excision efficiency, we have
shown that the length of an AO is an important parameter
in design [34]. While "longer is better" in many instances
of single AO-induced exon skipping, this does not hold
true in all cases. This presumably arises through the mask-
ing of motifs involved in exon silencing or recognition, or
influence on secondary structure of the AO. It would
appear that combinations of the "best" AOs may not nec-
essarily lead to the optimal AO cocktails, at least for dys-
trophin exon 20, currently classified as a Type 4 exon.
The same trend in inducing exon 20 skipping was
observed in the mdx mouse dystrophin gene transcript.
Individual AOs were essentially ineffective and one AO
combination was most efficient at exon excision [26].
However, it was of interest to note that the AO annealing
coordinates of the AOs in the "mouse cocktail" were dif-
ferent from those directed at the human dystrophin gene
transcript, indicating that it may not be possible to extrap-
olate AO design from one species to another. Further
comparisons of induced exon skipping between the
mouse and human dystrophin gene transcripts are cur-
rently underway.
Dystrophin exon 65 skipping
Exon 65 was another dystrophin exon that was difficult to
exclude from the mature mRNA. Eight AOs were designed
to the donor and acceptor splice sites, as well as putative
SR protein binding sites as predicted by ESEfinder [23]
(Additional file 2 and Figure 2a). Exon 65 AOs were indi-
vidually transfected into cultured human myogenic cells
as cationic lipoplexes at concentrations of up to 600 nM,
but all except one AO failed to induce readily detectable
exon 65 skipping (Figure 2b). There was a trace of the
shortened transcript missing exon 65, less than 5%, in
response to transfection with AO 65.3 (H65A(+26+50))
at 600 nM, but exon 65 excision was not observed at lower
concentrations. However, while some AO cocktails were
found to be essentially inactive, other combinations were
very efficient at inducing exon 65 skipping. The AO cock-
tail of H65A(-11+14) and H65A(+26+50) was able to
induce 65% skipping after in vitro transfection at 100 nM
(data not shown). Subsequent titrations studies with this
AO cocktail indicated 35% exon 65 exclusion after in vitro
transfection at total concentrations of 10 nM, with 20%
skipping at 5 nm and 8% skipping at 2 nM, that is 1 nM
of each AO. Approximately 2% exon excision was detected
after 0.5 nM transfection, the lowest concentration tested
(Figure 2c). Individually, these AOs were unable to induce
any exon 65 skipping after transfection at concentrations
hundreds of fold greater, again indicating some synergy
between these compounds. We originally reported a 3 AO
cocktail for exon 65 removal [19], but subsequent studies
indicated equivalent efficiency with the combination of
only H65A(-11+14) and H65A(+26+50).
AO induced excision of human dystrophin exon 20Figure 1
AO induced excision of human dystrophin exon 20. 
Primary human myogenic cultures were transfected with cat-
ionic lipoplexes:AO preparations at the concentrations indi-
cated and incubated for 24 hours before total RNA was 
extracted. Nested RT-PCR was undertaken across exons 
18–26. The full-length and exon 20 deleted transcripts are 
represented by products of 1336 and 1094 bp, respectively. 
(a) Overview of AO annealing coordinates across dystrophin 
exon 20. (b) AO cocktail 20.1 and 20.2, (c) AO cocktail 20.1 
and 20.3, (d) AO cocktail 20.2 and 20.5, (e) AO cocktail 20.3 
and 20.4, (f) AO cocktail 20.5 and 20.6, (g) single AO 20.6.Page 3 of 8
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The use of AO cocktails is not limited to enhancing exon
removal from the dystrophin mRNA. In the case of
human dystrophin exon 10, a combination of 2 AOs was
required for specific exon excision. As with other recalci-
trant exons, several AOs described in Additional file 3,
were unable to induce any detectable removal of exon 10
when applied individually, except for H10A(-05+16),
which only excised exon 10 together with blocks of flank-
ing exons (data not shown). Several dystrophin tran-
scripts missing exons 10–12, 9–12, 9–14 and 9–15 were
sporadically detected, with 9–12 and 9–14 being most
commonly observed. These dystrophin transcripts are in-
frame and, extrapolating from a mildly affected Becker
muscular dystrophy patient missing exon 9–22 [27],
would be expected to produce a shorter dystrophin that
could be of near-normal function. Two AOs, H10A(-
09+16) and H10A(-05+24) that overlapped H10A(-
05+16) had no effect on the processing of the dystrophin
transcript (data not shown).
Some AOs directed at other parts of the dystrophin gene
transcript had been shown to remove one or two exons in
addition to the target, and this was assumed to reflect
highly coordinated processing of both exons. Targeting
human or canine dystrophin exon 8 always leads to tran-
scripts missing exons 8 and 9 [11,19], whereas directing
AOs to human exons 17, 34 or 54 induces transcripts
missing the targeted exon as well as 17+18, 34+35 and
54+55 respectively [19].
The induced skipping of exon 10 was distinct from these
cases in that larger blocks of exons were involved, and the
resultant patterns were somewhat variable. However,
upon combining H10A(-06+15) with H10A(+98+119) or
H10A(+130+149), specific exon 10 excision could be
achieved, although there was still some evidence of addi-
tional shortened transcripts induced by the individual
AOs.
Trends in AO cocktail design
Additional file 4 provides an overview of the predicted
ESE splice motifs masked by the AOs reported in this
study, with an indication of the maximum score and
number of motifs shown in brackets. One feature that was
common to all effective AO cocktails directed to exon 10,
20 and 65 was the targeting of predicted SC35 motifs by
both AOs in the mixture. We do not propose that pre-
dicted SC35 motifs are the most important targets for
induced exon skipping, as 8 out of 41 AOs targeting Type
1 exons, that are removed at high efficiency, do not appear
to be directed at any predicted SC35 motifs [19]. The rel-
evance of the SC35 motifs to induced exon skipping is not
known and requires further investigation.
Dystrophin exon 67 had previously been classified as a
Type 3 exon, that is, only low levels of exon skipping were
induced by the single AO, H67A(+22+47) [19]. This AO
was predicted to anneal to 3 SC35 motifs and, while sub-
stantial exon skipping was induced after transfection at
600 nM, weaker skipping at 300 nM and there was no
detectable skipping at lower concentrations. However,
upon combination of H67A(+22+47) with either of two
other AOs directed at the acceptor, H67A(-10+17), or
donor site H67D(+11-14), 50% exon 67 skipping was
generated after transfection at 50 nM, with 42% and 23%
exon 67 skipping induced after transfection at 10 and 2
nM, respectively (data not shown). The AOs directed at
the exon 67 acceptor and donor sites were shown to be
inactive when used individually at concentrations of 600
nM, and neither was directed to predicted SC35 motifs.
Although the exon 67 cocktails do not conform to the
observation that AOs targeting SC35 motifs are more
effective in cocktails, this may reflect on the AO common
to both cocktails, H67A(+22+47), which targeted three
SC35 motifs and exhibited substantial exon skipping
potential when applied at high concentrations.
AO cocktails that induced the most pronounced exon
skipping did not necessarily block donor and acceptor
sites, and other splicing motifs, nor did the most effective
AO combination correlate with the total number of ESE
sites targeted. For example, the most effective cocktail for
AO induced excision of human dystrophin exon 65Figure 2
AO induced excision of human dystrophin exon 65. 
Primary human myogenic cultures were transfected with cat-
ionic lipoplexes:AO preparations at the concentrations indi-
cated and incubated for 24 hours before total RNA was 
extracted. Nested RT-PCR was undertaken using primers 
directed to exons 63–68. The full-length and exon 65 deleted 
transcripts are represented by products of 618 and 416 bp, 
respectively. (a) Overview of AO annealing coordinates 
across dystrophin exon 65, (b) Single AO transfection with 
65.5, 65.3 and 65.7, (c) AO cocktail 65.1 and 65.3. Note that 
the upper concentration of AO:lipoplex administered to 
these cells was 10 nM in total.Page 4 of 8
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three SC55 motifs, a single SF2/ASF and a SRp40 site. In
contrast, a less effective AO combination directed at the
same exon was directed at 4 SC35 sites, 2 SF2/ASF, 2
SRp40 and a single SRp55 motif. Exons 10 and 65 are
removed by AOs directed at the acceptor site and internal
ESE's, while exon 20 AOs anneal to internal ESE's.
H10A(+98+119) and H65A(+63+87), annealed to all four
predicted SR binding sites (SF2/ASF, SC35, SRp40 and
SRp55), and these AOs were inactive when used individu-
ally.
AO chemistry comparisons in cocktails
The 2OMeAOs have some advantages over other AO
chemistries, including PMOs, in that they can be readily
synthesized in-house and may be efficiently transfected
into cultured myogenic cells as cationic lipoplexes. PMOs
are not readily taken up by cultured cells, unless high
transfection concentrations are applied, scrape loading is
employed [28,29], or the PMOs are coupled to cell pene-
trating peptides to enhance delivery [30-32]. We have
undertaken other comparisons between the 2OMeAOs
and the PMOs directed at the mdx mouse nonsense muta-
tion in exon 23 and observed that the PMOs offer much
greater potential in vivo [16,17,33]. We now extend these
studies to other targets, including dystrophin exons that
had been difficult to displace and have found the same
trends in exon skipping are observed with both chemis-
tries.
PMOs directed to the same coordinates as the 2OMeAOs,
H20A(+44+71) and H20A(+147+168), were unable to
induce any detectable skipping of human exon 20, despite
being transfected individually at concentrations of up to
20 µM (Figure 3a and 3b). However, as with the corre-
sponding 2OMeAOs, a combination of the two PMOs
resulted in substantial exon 20 skipping after transfection
at a total concentration of 5 µM, that is 2.5 µM of each
PMO (Figure 3c). These particular PMOs did not carry a
peptide tag to enhance delivery, hence the transfection
concentration was substantially higher than that used by
the 2OMeAO cationic lipoplexes. Subsequent experi-
ments have shown that exon 20 could be excised with the
PMO cocktail at total concentrations as low as 1 µM (data
not shown), whereas the individual PMOs could not
induce skipping at concentrations 40-fold higher.
Chemistry comparisons in AO design
We have previously reported that the length of an AO can
play an important role in the ability of that compound to
induce exon skipping [34]. One mdx mouse model of
muscular dystrophy has a nonsense mutation in exon 23
[35], and has been useful in optimizing AO design
[8,9,34,36] and comparing different chemistries [15,17].
We have shown that the donor splice site of mouse dys-
trophin exon 23 was an amenable target for redirecting
splicing and demonstrated a 25 mer, M23D(-7+18) was
more efficient than a shorter AO, M23D(+2-18). The latter
compound was in turn found to be more efficient at
inducing exon 23 excision than 2 longer AOs, M23D(+12-
18 and M23D(+7-23) [34]. This same hierarchy of exon
23 skipping was also observed when these sequences were
prepared as PMOs, coupled with cell penetrating peptides,
and evaluated in cultured cells. RNA was extracted 24
hours after transfection, and as can be seen in Figure 4, the
25 mer, M23D(+7-18), induced superior exon skipping to
the 20 mer, which in turn was more effective than both 30
mers, M23D(+12-18) and M23D(+7-23). At later time-
points (data not shown), it was possible to establish that
PMO M23D(+7-23) was marginally more effective at exon
23 removal than the other 30 mer, confirming the trends
shown by the 2OMeAOs [34]. In addition, the shortest
products in Figure 4 correspond to dystrophin gene tran-
scripts missing exons 22 and 23, products that are also
generated in response to transfection with 2OMeAOs and
previously reported [9,36]. Thus trends seen with the
2OMeAOs in terms of ranking of efficiency of overlapping
AOs, synergy when applied in cocktails and the more
effective compounds also promoting exclusion of exons
22 and 23, correlate to those observed with the PMOs.
Induced skipping of human dystrophin exon 20 with PMOsFig re 3
Induced skipping of human dystrophin exon 20 with 
PMOs. Primary human myogenic cultures were transfected 
with PMOs at the concentrations indicated and incubated for 
24 hours before total RNA was extracted. Nested RT-PCR 
amplified between exons 18 and 26. The full-length and exon 
20 deleted transcripts are represented by products of 1336 
and 1094 bp, respectively. (a) Individual PMOs directed to 
exon 20. (b) PMO cocktail directed to exon 20. Note that 
the total concentration of PMOs is shown, ie, 5 µM indicates 
2.5 µM of each PMO.Page 5 of 8
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induce skipping of Type 1 exons [19] have now been pre-
pared as PMOs (n = 41). These PMOs were shown to
induce the same dystrophin exon removal patterns as
those generated by the corresponding 2OMeAOs after
transfection in either primary human myogenic cultures
or muscle explants (data not shown). Detailed compari-
sons of sub-optimal PMOs to other dystrophin targets has
not been undertaken, as the perfect concordance observed
to date between the exon skipping trends with 2OMeAOs
and PMOs would suggest that this would be unnecessary
and a waste of resources. Our efforts are being directed to
fine-tuning the next series of PMOs likely to enter clinical
trials, as well as improving upon the efficiency of excision
of Type 2 and 3 dystrophin exons, through improved AO
design, and/or the use of AO cocktails. It will also be of
interest to revisit some of the Type 1 dystrophin exons that
are efficiently removed with a single AO, to ascertain if the
application of AO cocktails can further enhance exon
removal at very low AO concentrations. Although the use
of AO cocktails will require the synthesis of two different
compounds, these AOs would be used as a single prepara-
tion and safety evaluation would be undertaken on the
combination. Should an AO cocktail be ten-fold more
effective that an optimal single AO to induce targeted
exon excision, there would be clear production and cost
benefits. Perhaps more importantly, the use of AO cock-
tails may address safety and efficacy issues in that lower
amounts of an AO preparation will need to be adminis-
tered.
Conclusion
AO induced exclusion of dystrophin exons during pre-
mRNA processing offers a potential treatment for remov-
ing or by-passing protein-truncating mutations that lead
to DMD. For induced exon skipping to be a viable ther-
apy, the most effective AO preparations must be devel-
oped so that minimal amounts can be administered.
Many dystrophin exons could be efficiently removed from
the mature mRNA by the intervention of a single AO dur-
ing dystrophin pre-mRNA processing. Some exons require
the action of two AOs, often ineffective when used indi-
vidually, which somehow act in a synergistic fashion, pre-
sumably through prevention of spliceosome assembly by
altering pre-mRNA folding or masking crucial protein
binding sites. The SC35 motif appears to play some role as
an amenable target for AO cocktails, but this association
is not absolute. Clearly, there are many parameters
involved in interfering with the pre-mRNA splicing proc-
ess remaining to be elucidated. The trends in splice inter-
vention may be seen with AOs composed of 2 different
chemistries, 2OMeAO and PMO.
Methods
AO design and synthesis
2OMeAOs were prepared on an Expedite 8909 Nucleic
acid synthesiser using the 1 µMol thioate synthesis proto-
col. AOs were designed to anneal to splicing motifs at the
intron: exon boundaries, as well as ESE motifs predicted
by the web based application, ESEfinder[23].
PMOs, and PMOs conjugated to the cell penetrating pep-
tide, were synthesized by AVI Biopharma (Corvallis, Or).
AO nomenclature is based upon that described by Mann
et al, 2002 [36]. The first letter designates the species, the
number indicates the exon, the second letter specifies
Acceptor or Donor splice sites, with the -/+ and numbers
representing the annealing coordinates in the intronic and
exonic domains respectively. For example, H65A(-11+14)
would anneal across the acceptor site of human dys-
trophin exon 65, specifically to the last 11 bases of intron
64 and the first 14 nucleotides of exon 65.
Culture and transfection – Primary human myoblasts
The preparation of primary human myoblasts is described
by Rando and colleagues, 1994 [37]. Primary human
myotubes were transfected in Opti-MEM (Invitrogen), 48
hrs after seeding, with Lipofectamine 2000 (L2K): AO at
1:1 w:w ratio according to manufacturer's instructions
(Invitrogen). For each experiment, transfections were
repeated three times to confirm reproducibility.
Culture and transfection – H-2Kb-tsA58 (H2K) mdx 
myoblasts
H2K-Mdx myoblasts [38] were cultured as described by
Mann and colleagues 2001 [9]. AOs were transfected with
Lipofectin:AO at 2:1 w:w ratio, 24 hrs after seeding. Lipo-
fectin was used according to manufacturer's instructions
(Invitrogen, Melbourne). All transfections occurred in
duplicate wells and were repeated three times to ensure
consistency.
Induced skipping of mouse dystrophin exon 23 with overlap-ping PMOs directed at th onor splic  siteFig re 4
Induced skipping of mouse dystrophin exon 23 with 
overlapping PMOs directed at the donor splice site. 
Immortalised H2K-mdx myotubes were transfected with 
PMOs at the concentrations indicated and incubated for 24 
hours before total RNA was extracted. Nested RT-PCR was 
undertaken to amplify exons 20 and 26. The full-length and 
exon 23 deleted transcripts are represented by products of 
901 and 688 bp respectively. The band of 542 bp corre-
sponds to dystrophin gene transcripts missing both exons 22 
and 23 and has been previously reported [9, 36].Page 6 of 8
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RNA extraction and RT-PCR have been described previ-
ously [8,9]. Briefly, RNA was purified from duplicate cul-
tures using an acid phenol extraction, before a one step
RT-PCR was undertaken using specific primers, template
and the Invitrogen Superscript III. After 30–35 cycles of
amplification, an aliquot was removed and subjected to
nested PCR using inner primer sets. Details of all primers
used in these experiments are available upon request. The
identity of the RT-PCR products was confirmed by direct
DNA sequencing [39]. Estimates of relative exon skipping
efficiency were performed using the Vilber Lourmat
Chemi-Smart 3000 system with Chemi-Capt software for
image acquisition and Bio-1D software for image analysis.
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